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Abstract: Many types of biosensors employ magnetic nanoparticles (diameter = 5–300 nm) 
or magnetic particles (diameter = 300–5,000 nm) which have been surface functionalized 
to  recognize  specific  molecular  targets.  Here  we  cover  three  types  of  biosensors  that 
employ different biosensing principles, magnetic materials, and instrumentation. The first 
type consists of magnetic relaxation switch assay-sensors, which are based on the effects 
magnetic  particles  exert  on  water  proton  relaxation  rates.  The  second  type  consists  of 
magnetic  particle  relaxation  sensors,  which  determine  the  relaxation  of  the  magnetic 
moment within the magnetic particle. The third type is magnetoresistive sensors, which 
detect  the  presence  of  magnetic  particles  on  the  surface  of  electronic  devices  that  are 
sensitive to changes in magnetic fields on their surface. Recent improvements in the design 
of  magnetic  nanoparticles  (and  magnetic  particles),  together  with  improvements  in 
instrumentation, suggest that magnetic material-based biosensors may become widely used 
in the future. 
Keywords:  magnetic  particles;  magnetic  nanoparticles;  target  molecules;  biosensors; 
magnetization 
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1. Introduction 
Nanoscale magnetic materials are an important source of labels for biosensing due to their strong 
magnetic properties which are not found in biological systems. Modulation of the composition, size 
and magnetic properties of these materials permits their use in a variety of instruments and formats for 
biosensing  [1,2].  New  types  of  instrumentation  are  promising  for  the  use  of  nanoscale  magnetic 
materials  in  point  of  care  sensors  in  variety  of  applications.  Here,  we  cover  three  biosensors  that 
employ  magnetic  nanoparticle  labels  with  different  sensing  principles  and  instrumentation:  
(i)  magnetic  relaxation  switches,  (ii)  magnetic  particle  relaxation  sensors,  and  (iii)  magnetoresistive 
sensors. 
2. Magnetic Relaxation Switches (MRSws) 
Superparamagnetic nanoparticles made of iron oxide and a polymeric coating are clinically proven 
magnetic resonance (MR) contrast agents and widely used in pre-clinical, targeted molecular imaging 
applications [2,3]. When used as targeted contrast agents, surface-modified nanoparticles (NPs) bind 
specific  molecules  producing  local  inhomogenieties  in  the applied magnetic field in tissues where 
molecular targets are present. These inhomogeneities result in decreases in the T2 relaxation time (or 
increases  in  1/T2,  the  T2  relaxation  rate),  and  these,  in  turn,  lead  to  changes  in  the  contrast  of  
MR images. 
Figure 1. Principle of Type I MRSws. Dispersed magnetic nanoparticles (NPs) form an 
aggregate upon binding with target analytes (triangle). The aggregated form of the NPs 
dephases the spins of the surrounding protons of water molecules more efficiently than NPs 
present as the dispersed state. The effect is observed as a decrease in spin-spin relaxation 
time, T2 (reproduced with permission from reference [52]). 
 
 
Recently, Josephson and collaborators exploited the change in T2 produced by magnetic NPs to 
obtain  MR  based  assays  called  Magnetic  Relaxation  Switches  (MRSws).  The  principle  of  MRSw 
assays is illustrated in Figure 1; NPs switch between dispersed and aggregated states, and associated 
with the change in aggregation are changes in the spin-spin relaxation time (T2), the basis of which is 
discussed  below  [4].  The  materials  used  in  MRSw assays are either magnetic nanoparticles (NPs, Sensors 2009, 9                         
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diameter 5–300 nm) or micometer-sized magnetic particles (MPs, diameter 300–5,000 nm). As shown 
in  Figure  1,  MRSws  are  homogeneous  particle  aggregation/disaggregation-based  assays  similar  to 
aggregation assays using Latex particles, red blood cell hemagglutination, and antibody reactions with 
proteins  (nephelometry).  Unlike  optically-based  assays,  MRSws  employ  radiofrequency  radiation 
which penetrates biological samples regardless of their optical properties [5]. Since the dispersed and 
aggregated states of NPs (or MPs) can be reversed by such factors such as temperature, pH, and a high 
concentration  of  competing  analytes,  and  hence  are  referred  to  as  “relaxation  switches”.  The 
aggregated and dispersed states of magnetic NPs or MPs have different transverse spin-spin relaxation 
times (values of T2). NP aggregation and the size range of the resulting aggregates depends on the type 
of analyte and analyte concentration [6].  
2.1. Mechanism of MRSws 
MRSw assays exploit the fact that for both nanoparticles (NPs) and larger magnetic particles (MPs) 
transverse relaxation times (T2) differ between dispersed and aggregated states. However, for Type I, 
NP-based  systems,  T2  decreases  with  the  aggregation,  while  with  type  II,  MP-based  systems  T2 
increases with aggregation. The basis of this is as follows [6–8].  
The general theory of how magnetic spheres alter T2 is termed outer sphere relaxation theory. This 
theory uses two parameters of Dw and tD. Dw is the difference in angular frequencies between the local 
field  experienced  by  a  proton  at  the  equatorial  line  of  the  sphere's  surface  and  in  the  bulk  
(Dw = mOMg/3, where mO is the vacuum magnetic permeability, M is the particle magnetization, and g 
is the proton gyromagnetic ratio). Then tD is the translational diffusion time of water around the sphere 
(tD = Ra
2/D, where Ra is the sphere radius and D is the water diffusion coefficient). The outer sphere 
diffusion theory is applied when the motional average condition is fulfilled as DwtD < 1 [7,8]. In this 
condition, the relaxation rate R2 (= 1/T2) increases as the sphere's size is increased. As the definitions 
of Dw and tD imply, the motional average condition is not fulfilled with increased size of the particles 
such as MPs (DwtD > 1) and the relaxation rate of 1/T2 decreases with the formation of MP aggregates. 
See the detailed discussion of this phenomenon in a review [8]. 
Thus, when present in solution magnetic NPs (or MPs) induce local magnetic field inhomogeneities, 
which  cause  a  dephasing  (loss  of  phase  coherence)  of  the  proton  spin  precession,  and  these 
inhomgeoneities lead to a reduction of the T2 relaxation time. When NPs aggregate (Type I MRSw), a 
smaller number of larger magnetic field inhomogeneities result. These larger inhomogeneities are more 
effective dephasers of proton relaxation and T2 drops. Here DwtD < 1. When MPs aggregate (Type II 
MRSw), a smaller number of larger magnetic field inhomogeneities again results. However, there now 
so few aggregates, and spaces between them so great, that many water proteins fail to diffuse in and out 
of  these  homogeneities  during  the  time  course  of  the  measurement.  This  is  termed  the  "diffusion 
limited case" for the enhancement of proton relaxation by magnetic microspheres. Here DwtD > 1. 
Relaxivity is an important measure of the potency of magnetic materials and an important factor to 
selecting evaluating materials for use in MRSw assays. Materials with higher relaxivities are more 
detectable by the relaxometry and can detect lower concentrations of analyte [8]. Sensors 2009, 9                         
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R2 = (1/T2(+) – 1/T2(−))/C               (1) 
where  R2  is  relaxivity  of  the  particle  (in  moles  of  metal)  expressed  as  (mM  sec)
−1,  C  is  the 
concentration of the paramagnetic center in mM, and 1/T2(+) and 1/T2(−) are the transverse relaxation 
rates (sec
−1) in the presence and absence of the nanoparticle, respectively. C is typically expressed as 
the concentration of paramagnetic metal, but it can also be expressed as the concentration of NPs or 
MPs in solution. Here the R2 per metal is multiplied times the number of paramagnetic metal atoms per 
particle.  Magnetic  particles  with  larger  numbers  of  metals  per  particle  are  more  potent  in  MRSw 
assays, see below. 
2.2. Magnetic Particles 
Magnetic particles can be categorized by their size, with nanoparticles (NPs) being between 10 and 
300 nm in diameter, while larger magnetic particles (MPs) are between 300 and 5,000 nm in diameter. 
Since the first publication demonstrating the MRSw assay principle in 2001 [4], NPs with surfaces of 
cross-linked iron oxide (CLIO) have been used for sensing for analytes ranging from small molecules 
to mammalian cells [5,9–12]. CLIO is an excellent NP both for in vivo MR imaging [13] and for 
MRSw assay applications, because of its stability in a variety of fluids, including aqueous buffers and 
blood, and because of its functional handle of amino groups. CLIO is prepared by two-step treatment of 
the monocrystalline iron oxide nanoparticle known as MION. The MION NP features a dextran coating 
which is first cross-linked with epichlorohydrin and then reacted with ammonia to obtain amino groups 
on the crosslinked dextran surface. MION and CLIO NPs have an iron oxide cores of about 5 nm in 
diameter and dextran shell (or crosslinked dextran shell) about 10 nm in thickness, so that both NPs 
have overall diameters between 25 nm and 30 nm. 
Recently, magnetic NPs and MPs with improved magnetic properties, and higher detectability per 
particle,  have  been  described  for  use  with  in  vivo  MR  imaging  and  in  vitro  biosensor  
applications [1,14,15]. One strategy is to increase the R2 relaxivity of NPs by increasing M or d, since 
R2 is proportional to M
2d
2. Here M is the saturation magnetization per mole of metal or per gram of 
metal atoms within the particle and d is the particle diameter. [16–18]. Core/shell NPs have been 
designed with Fe metal cores (not iron oxide cores) and these have an increased Ms and a thin iron 
oxide shell to block oxidation metal oxidation. They show an enhanced sensitivity compared to CLIO 
for the detection of bacterial cells [17]. Another strategy employs Mn-doped metal oxide NPs; these 
also have high Ms and high R2s, and have been synthesized with sizes of 10, 12 and 16 nm. These NPs 
have  been  used  in  the  sensitive  detection  of  unprocessed  cancer  cells,  with  as  few  as  two  cells  
per  1  mL  being  detected  with  miniaturized  relaxometer  [16].  Another  approach  to  improving  the 
sensitivity of MRSw assays is the use of MPs rather than NPs. These MPs have far more metal atoms 
per particle than NPs and a far larger per magnetic moments per particle, even though their values or M 
per  metal  are  typical  of  older  NPs  [6,19].  In  an  MRSw  assay  of  immunoreactive  antibodies  to 
influenza, MPs of 1 mm in diameter were employed that had a similar R2 relaxivity to CLIO NPs on a 
per iron atom basis. However, the larger MPs had 350,000 fold more irons per particle than CLIO NPs. 
In the MRSw assay for anti-Tag peptide antibody, MPs had 186,000 fold enhanced sensitivity (relative 
to CLIO). The improvement in sensitivity was achieved by a combination of factors including the use Sensors 2009, 9                         
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of the larger MP, magnetic field-assisted aggregation of MPs, and valency enhancement achieved by 
the addition of a secondary antibody [19]. Figure 2B provides a schematic version of the improvement 
in assay sensitivity shows these techniques.  
Figure  2.  Methods  for  the  improvement  in  MRSw  assay  sensitivities.  (A)  MPs  (￿) 
aggregate  in  a  homogeneous  magnetic  field,  whereas  NPs  (￿)  do  not  respond.  A  T2 
increase in time is observed in a 0.47 T field (gray) in an MP solution, but not in an NP 
solution. The T2 value of the MP solution decreases as the MPs are dispersed with the field 
turn-off (white). Note that a T2 increase is observed with MP aggregation. (type II MRSw). 
Since this effect is slowed by the viscosity of the medium, T2-based viscometer can be 
obtained, see [7]. (B) Three strategies for enhancing the sensitivities with a type II MRSw 
assay. (a) A decreased concentration of MPs formed aggregates at a lower concentration of 
analyte (anti-Tag antibody) than that of NPs. MPs are larger than NPs and used at a lower 
concentration. (b) Application of a magnetic field (0.47 T) induced aggregation of MPs as 
in  (A)  and  accelerated  the  interaction  between  MPs  and  analytes.  (c)  Target  valency 
enhancement by addition of a secondary antibody (sheep anti-mouse). The valency increase 
of targets from two (anti Tag) to four (anti Tag:anti mouse) enhanced MRSw sensitivities. 
Figure reproduced with permission from reference [6]. 
 
 
The stability of NPs or MPs in solution is another important factor in selecting materials for use in 
MRSw  assay  applications.  Stabilization  can  be  achieved  by  charge  effects  leading  to  electrostatic 
repulsion between particles or by the use of hydrophilic polymeric coatings that block particle/particle 
aggregation [8]. Coatings of polymeric dextran make NPs extremely stable and therefore suitable for 
both in vivo MR and in vitro MRSw assay applications [20]. Attachment of 10 kDa polyethylene glycol 
(PEG) diamine on the surface of MPs exchanged the initial electrostatic stability of the negatively 
charged MPs to polymer-based stability and was necessary to use the MPs in MRSw applications [19]. 
Table 1 reviews the magnetic particles used in MRSw biosensing applications.  
 Sensors 2009, 9                         
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Table 1. Characteristics of magnetic particles used for biosensing applications. 
Particle  Size  Composition  Characteristics  Reference 
CLIO  ~30 nm  5 nm core, 10 nm dextran 
coating 
MRSw, 
R2 = 50 (s×mM Fe)
-1 
[5] 
Core/shell  16 nm  Fe core, iron oxide shell, 
2.5 nm shell thickness 
MRSw, 
R2 = 260 (s×mM Fe)
-1 
[17] 
Mn-MNP
a  16 nm  Mn-doped iron oxide  MRSw, 
R2 = 420 (s×mM 
metal)
-1 
[16] 
MP  1000 nm  Commercial (Dynabeads)  MRSw, 
R2 = 43 (s×mM Fe)
-1 
[19] 
Iron oxide  56 nm  Commercial (Quantum 
Magnetics, Miltenyi 
Biotech) 
SQUID  [35,36] 
Iron oxide  19.5 nm    AC susceptometer  [42] 
Cubic FeCo  12.8 nm  1.5 nm oxidized shell  GMR  [49] 
SAF
b  100 nm  Multilayers of 
ferromagnetic, interlayer 
of nonmagnetic material 
GMR, 
disk shape 
[47] 
Magnetic bead  130, 250 nm  Commercial (Micromod 
Partikeltechnologie) 
SQUID  [43] 
(a) MNP: magnetic nanoparticle, (b) SAF: synthetic antiferromagnetic. 
 
2.3. Instrumentation  
Point of care (POC) sensors would benefit home users, clinicians and physicians, and aid in the 
preparations  for  bio-warfare  and  pandemics.  The  miniaturization  of  MR  relaxometers  holds  great 
promise for use as instrumentation with POC [10,16,17,21]. 
The MR relaxometers used for MRSw assays have three basic components, a magnet, a coil, and a 
transceiver. Currently MRSw assays depend on the commercial bench top relaxometers such as the 
0.47 T Minispec, 20 MHz instrument made by Bruker, Billerica, MA [5, 19]. High throughput MRSw 
assays have been demonstrated in 384-well plates through the use of a 1.5 T MR scanner [5,22,23]. 
However, the relaxometer and MR scanner above are impractical as POC sensors due to their high 
cost, which results principally from the large magnets employed and lack of miniaturized electronic 
components [21].  
The  magnets  used  in  relaxometers  can  be  relatively  weak  (0.1  to  0.5  T)  and  can  provide  less 
homogeneous  magnetic  fields  than  those  used  in  MR  imagers.  One  of  the  first  miniaturized  MR 
relaxometry systems consisted of a small palm-sized permanent magnet and on-board NMR electronics 
and  planar  microcoils  with  integrated  microfluidic  channels  [10]  (see  Figure  3A).  A  multiplexed 
detection  of  biomarkers  was  achieved  using  an  8  microcoil  array  and  demonstrated  the  potential 
application  of  the  microNMR  system  for  high  throughput  MRSw  assays.  Optimization  of  circuit 
designing  in  development  of  RF  transceiver  integrated  circuits  led  to  a  small  but  complete  NMR 
system [21] (Figure 3B).  Sensors 2009, 9                         
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Figure  3.  (A).  Schematic  representation  of  a  miniaturized  chip-based  NMR  system, 
diagnostic magnetic resonance (DMR). (B). NMR based CMOS RF biosensor. A complete 
NMR system was built with a portable platform (reproduced with permission (A) from 
reference [10] and (B) from reference [21]). 
 
 
2.4. Applications of Type I and Type II MRSw's 
As discussed above, magnetic particle aggregation induces T2 changes that are opposite in direction 
for  NPs  (T2  decrease,  type  I  MRSw)  and  MPs  (T2  increase,  type  II,  MRSw).  Applications  of  the 
different types of MRSw systems are discussed below. 
2.4.1. Type I MRSw  
The amino CLIO NP is a versatile NP for MRSw applications because it is sufficiently stable to 
permit a variety of surface chemistries [24–26]. CLIO surfaces have been designed to detect ions [12], 
DNA [4,5,27], proteins [5,9,19], and cells [10] such as bacteria and mammalian cells. A particularly 
valuable system for the study of MRSws is the reaction of NPs displaying the Tag peptide and reacting 
to a monoclonal antibody (anti Tag) binding to the peptide [6]. The formation of NP aggregates with 
anti-Tag  antibodies  has  been  shown  to  be  analogous  to  the  interactions  between  antibodies  and 
antigens, with a maximum complex formation occurring at the equivalence point as the concentration 
of analyte was increased. 
A variation of the type I MRSw aggregation/dispersion method is found with the miniaturized NMR 
system  (DMR:  diagnostic  magnetic  resonance).  This  system  achieves  a  high  assay  sensitivity  by 
reducing a sample volume to 5 mL and by using filtration methods [10]. Incorporation of microfluidic 
system with a filter unit into the miniaturized NMR system permitted the detection of bacteria, with as 
few as 20 colony-forming units per mL of sputum being detected [17]. The size discrepancy between 
target bacteria and NP probes allowed filter-based concentration of NP-bound bacteria while filtering 
out unbound NPs. 
Another important application of the type I MRSw assay system is its use in an implantable MR Sensors 2009, 9                         
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based, water relaxation sensor. A semi-permeable membrane was employed with a size cutoff that 
permitted small analytes, like glucose, to diffuse in and out while the larger CLIO NPs were retained 
within the sensor [25]. Continuous monitoring of the T2 values of the solution inside the membrane 
showed a competitive assay type-response of glucose-functionalized CLIO to glucose [23,25]. The 
proof  of  concept  sensing  obtained  with  glucose  was  translated  to  an  implantable  water  relaxation 
sensor detecting hCG as a cancer biomarker [28,29]. The implantable device had a reservoir that was 
covered  with  a  semi-permeable  polycarbonate  membrane  and  contained  CLIO  functionalized  with 
antibodies to the hCG cancer biomarker. In vivo MR imaging was used to monitor the T2 values from 
inside the sensor device. When implanted in a tumor bearing mouse model, the MR signal from the 
sensor showed significant decreases in 1-4 days due to diffusion of the cancer biomarker hCG into the 
reservoir and the resulting aggregation of the CLIO NP.  
2.4.2. Type II MRSw 
Type  II  MRSws,  where  biomolecules  are  attached  to  MPs  and  aggregated  by  reaction  with 
molecular targets, exhibit an increased T2 when aggregated by reaction with a target analyte. With their 
greater numbers of iron atoms per particle, MPs can be used at concentrations far below than that of 
NPs  in  MRSw  assays.  With  the  lower  concentration  of  MPs,  lower  concentrations  of  analyte  are 
needed to induce aggregation and this results in greatly improved sensitivity [6,19]. 
When placed in a homogeneous magnetic field, MPs with charge-based or polymer layer-based 
stability, will aggregate, while NPs will not respond in this fashion [6,7,19,30–33]. The magnetic field-
induced MP aggregation is lost when the magnetic field was removed and Brownian effects break 
down aggregates. The rate of self-assembly formation of MPs in a magnetic field is a function of 
viscosity and can be used to make a T2 based viscometer. See Figure 2A and [7]. Recently, magnetic 
field-induced  MP  aggregation  has  also  been  used  to  accelerate  analyte-mediated  formation  of  MP 
aggregates [19,31,34].  The  applied  magnetic  field  enhanced  the  kinetics  of  molecular  interactions 
between multivalent analytes, (e.g., a monoclonal Tag antibody), and multivalent MPs displaying the 
Tag peptide. This technique is referred to as magnetic field enhanced target aggregation and shown in 
Figure 2B, frame (b).  
3. Magnetic Particle Relaxation-Based Sensors 
The relaxation of the magnetic moments within magnetic particles have been used as a basis for 
magnetic particle-based assays.  
3.1. Theory 
Magnetic particles in a liquid, with magnetic moments aligned by an applied magnetic field, employ 
two  relaxation  mechanisms  when  magnetic  field  is  turned  off:  (i)  Brownian  relaxation  and  
(ii) Néel relaxation. Brownian relaxation is governed by the physical rotation of the entire particle and 
characterized by the Brownian relaxation time, tB. Here:  
tB = 3VHh/kT               (2) 
where  VH  is  the  hydrodynamic  volume,  h  is  the  viscosity  of  the  medium,  k  is  the  Boltzmann’s Sensors 2009, 9                         
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constant, and T is the absolute temperature. The monodomain magnetic particle has an anisotropy 
energy, Ea, which is proportional to the crystal volume.  
Ea = KaV              (3) 
where Ka is the anisotropy constant and V is the volume of the crystal. When the applied field is 
removed, the magnetization vector within the particle returns to the lowest energy state along the easy 
axis with a characteristic Néel relaxation time, tN: 
tN = t0 exp(Ea/kT)            (4) 
where t0 is the preexponential factor that decreases as the anisotropy energy increases. Note that tN is 
an exponential function of the anisotropy energy that is proportional to the crystal volume.  
The effective relaxation rate is expressed as the sum of the Brownian relaxation rate and the Néel 
relaxation rate:  
1/t = 1/tB + 1/tN             (5) 
As Equation (5) shows, faster relaxation time between the two governs the effective relaxation 
process. Target induced aggregation can decrease the rates of the Brownian or Neel relaxations and this 
assays for molecular targets are generated. See [8].  
3.2. Assays 
3.2.1. Néel Relaxation Sensors 
Superconducting Quantum Interference Devices (SQUIDs) have been used for measurements of the 
relaxation  of  particle  magnetic  moments.  The  Brownian  relaxation  is  much  faster  than  the  Néel 
relaxation. For a 20 nm single domain magnetite particle in solution, the calculated relaxation times 
were  tB  ~1  ms  and  tN ~1  s  [35].  The  difference  in  the  relaxation  time  scales  was  a  basis  for  a 
homogeneous immunoassay [35] and a bacterial detection [36]. See Figure 4. The Brownian relaxation 
time scale of a single unbound magnetic particle was so short, it was out of the detectable range 
between 1 ms and 1 s of the SQUID. The free Brownian rotation of particles was then restricted when 
the magnetic particles bound a bacterium. The Néel relaxation was within the detection window of a 
SQUID,  which  was  used  to  determine  the  relaxation  time  of  surface  bound  particles.  The  
SQUID-based detection of the Néel relaxation time showed a limit of detection of 5 ´ 10
4 NPs for a 
substrate based assay and 1.1 ´ 10
5 bacteria in a 20 mL sample volume. Development of a gradiometer 
instead of a magnetometer suggested a two-order improvement in sensitivity was possible [37].  
3.2.2. Brownian Relaxation Sensors 
Measurements  of  static  and  dynamic  magnetic  susceptibility  using  alternate  currents  (ac)  have 
permitted use of the Brownian relaxation of NPs for biosensing. As Equation (2) suggests, the NP 
aggregates that form in recognition of target analytes have a larger hydrodynamic size and thus show 
slower  Brownian  relaxation  responses  than  a  single  NP.  The  resulting  decrease  in  relaxation  was 
sensed in buffer [38], and in serum [39] by using a SQUID or an ac magnetosusceptometer [39].  Sensors 2009, 9                         
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Figure 4. Principle of a SQUID-based homogeneous detector of bacteria. A. A pulse-form 
magnetic  field  orients  the  magnetic  moments  of  NPs.  B.  After  the  field  pulse  is  over, 
Brownian  motion  randomizes  the  magnetic  moments  of  unbound  NPs.  However,  the 
Brownian rotations of NPs bound to the bacteria are restricted. The bound NPs undergo 
Néel relaxation for reorientation of the magnetic moments. The SQUID detects the slower 
Néel relaxation for the bound NPs (reproduced with permission from reference [36]). 
 
 
Conolly and St. Pierre proposed using the dynamic magnetic properties of NPs in assays [40]. A 
complex magnetic susceptibility expresses the response of NPs as a function of an alternating magnetic 
field. According to their theory, the imaginary part has a peak when the frequency equals the inverse of 
the effective magnetic relaxation time [41]. Brownian relaxation is the dominant relaxation process for 
these NP based assays. When NPs form molecular target induced aggregates, the hydrodynamic radius 
is increased and thus decrease of the peak frequency is observed. An antibody was detected at the 
sensitivity of 0.05 mg/mL (= 0.3 nM) with an AC susceptometer [42]. Recently a volume amplified 
magnetic nanobead assay showed a dynamic magnetic property-based detection of DNA detection, 
albeit with an amplification strategy [43]. Here the presence of two different size NPs in a sample 
provided a high detection of target DNA molecules following a deconvolution of the magnetization 
data [44].  
4. Magnetoresistive Sensors 
Magnetoresistive sensors are based on the binding of magnetic particles to a sensor surface and the 
magnetic fields of the particles alter the magnetic fields of the sensor which result in electrical current 
changes within the sensor. There are two mechanisms through which magnetic particles bind to the 
sensor surface: (i) direct labeling and (ii) indirect labeling (a sandwich type binding). Magnetic probes 
bind to the surface functionality on the surface in direct labeling by using streptavidin-biotin interaction 
or  complementary  DNA  sequence  recognition.  Indirect  labeling  uses  the  principle  of  sandwich Sensors 2009, 9                         
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immunoassay in ELISA. For example, antibodies that bind to the target protein are immobilized on the 
surface. After treatment of the surface with a sample solution containing the target proteins, second 
antibodies that are biotinylated are added to the system. Finally Streptavidin coated magnetic particles 
are applied for tagging the biotinylated antibodies.  
Giant magnetoresistance (GMR) spin valve (SV) or magnetic tunnel junction (MTJ) sensors have 
been  successfully  used  to  sense  MPs.  Sensors  are  composed  of  multiple  layers  of  ferromagnetic 
materials. A biologically active molecule can be deposited on an Au layer or SiO2 layer to obtain a 
surface for the attachment of biomolecules. For a review of the structure of magnetoresistive sensors 
see [45]. 
Superparamagnetic particles with different sizes have been used in magnetoresistive biosensing. 
Earlier applications used relatively large magnetic particles, with diameters between 0.1 and 3 mm [46]. 
Micrometer sized particles have the advantages of facile observation under light microscope and a 
higher  particle-based  magnetic  moment  that  permits  detection  very  small  numbers  of  particles. 
However,  recently  magnetic  NPs  have  replaced  the  larger  particles  because  the  NPs  are  stable  in 
suspension  and  are  less  prone  to  particle  clustering  in  an  applied  magnetic  field  [45,47–49]. 
Streptavidin  coated  MPs  were  applied  to  spin  valve  sensors  in  the  protein  marker  detection  at 
27 pg/mL  level  of  sensitivity  [50].  By  using  50  nm  MACS  magnetic  nanoparticles,  Wang  and 
collaborators demonstrated cancer marker detection in 50% serum at sub picomolar concentrations [48] 
(Figure 5). 
Figure  5. A schematic representation of a giant magnetoresistive (GMR) sensor for an 
ELISA-type  protein  assay.  A.  The  probe  surface  was  functionalized  with  a  specific 
antibody, while the control surface was passivated with BSA. B. A sample solution was 
added for a specific binding of analyte proteins to the probe surface. C. A biotinylated 
antibody bound to the surface-immobilized analytes. D. Finally streptavidin-coated NPs 
were added for tagging the probe surface by biotin-streptavidin interaction. GMR signals 
were detected for sensing the presence of analytes on the surface. Courtesy from [48]. 
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Improvement of spin valve sensors was achieved by reducing the passivation layer to 30 nm and led 
to  an  enhanced  sensitivity.  A  signal  amplification  strategy  that  had  multiple layers of streptavidin 
coated  NPs  and  biotinylated  antibodies  in  the  sandwich  type  immunoassay  also  showed  enhanced 
signals. Multiplex sensing of different protein markers in serum was demonstrated on a single chip by 
carefully selecting antibodies and by employing the signal enhancing strategy with multiple layers of 
NPs.  Wang  and  his  group  in  Standford  University  used  nanoimprint  lithography  to  synthesize 
antiferromagnetic nanoparticles of 100 nm size with high magnetic moment and zero remanence [51]. 
The  antiferromagnetic  nanoparticles  that  have  a  disk  shape  were  composed  of  multiple  layers  of 
ferromagnetic material separated by a nonmagnetic interlayer. NPs with high magnetic moments were 
functionalized  with  streptavidin  and  permitted  the  detection  of  DNA  at  concentrations  as  low  as  
10 pM [47].  
Another effort to synthesize magnetic nanoparticles with high magnetic moment utilized cubic-
shaped FeCo nanoparticles of 12.8 nm in a GMR based sensor [49]. The cubic nanoparticles were 
surface functionalized with silane chemistry for attachment of Streptavidin or antibody. Direct labeling 
of biotinylated surface with Streptavidin coated nanoparticles allowed detection of 600 nanoparticle 
binding. Indirect labeling in ELISA type assay produced signals as low as 2 ´ 10
6 molecules of a 
biomarker protein.  
See  Table  2  for  a  review  of  assay  configurations  and  the  sensitivities  reported  for  them  in  
the literature. 
Table 2. Sensitivities of magnetic particle based biosensors. 
  Analyte 
Magnetic particle/ 
instrumentation 
Sensitivity 
Sample 
volume 
Reference 
MRSw 
type I 
nucleotide 
CLIO, bench top 
relaxometer 
Low nM~pM  300 mL  [4,5] 
proteins 
CLIO, bench top 
relaxometer 
Low nM  300 mL  [5,9] 
virus  CLIO, MRI  50 viruses/100 mL  100 mL  [11] 
bacteria  core/shell, DMR
a 
20 CFU
b/100 mL 
(membrane filetered) 
5 mL 
 
[17] 
Cancer cell  Mn-MNP, DMR  2 cells/1 mL  5 mL  [16] 
MRSw 
Type II 
antibody 
MP , bench top 
relaxometer 
<1 pM  300 mL  [19] 
AC 
suscepto
meter 
antibody  Iron oxide NP  <1 nM    [42] 
SQUID 
bacteria  Iron oxide NP  1.1 ´ 10
5 bacteria/20 mL    [36] 
DNA  Magnetic bead 
3~10 pM  
(signal amplification) 
  [43] 
GMR  Protein  Cubic FeCo NP  2 ´ 10
6 proteins  2 mL  [49] 
 
DNA  Antiferromagnetic NP  10 pM    [47] 
Protein  Iron oxide NP  2.4 pM    [48] 
(a) DMR: diagnostic magnetic resonance, (b) CFU: colony forming unit. Sensors 2009, 9                         
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5. Conclusions 
Magnetic NPs and MPs have been used in different types of biosensors based on different physical 
principles. Some achieve high sensitivity and, with rapid advances in instrumentation, maybe useful as 
point-of-care  sensors.  The  continued  rapid  development  of  sensors  using  magnetic  materials  
seems assured. 
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